Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Kalytera Therapeutics to Acquire COVID-19 Drug Developer Salzman Group.

Document Cited in Related
Vincent

MANews-(C)2009-2020

US-based pharmaceutical company Kalytera Therapeutics, Inc. (TSX Venture: KLY) (OTCQB: KALTF) has signed a binding letter of intent to acquire US-based drug developer Salzman Group, Inc., the company said.

Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the US, Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.

The group is developing R-107 for treatment of COVID-19 associated lung disease, chlorine inhalation lung injury and pulmonary arterial hypertension.

Subject to completion of customary due diligence, the company expects that definitive agreements will be executed by June 15, 2020.

In connection with this announcement, the company has requested that a trading halt of the company's common shares be affected in compliance with the requirements of the TSX Venture Exchange.

R-107 is a liquid prodrug of nitric oxide. Based on the fact that nitric oxide is an approved treatment for acute respiratory failure in newborns, and the clinical evidence of nitric oxide's antiviral activity against strains of coronavirus, Salzman Group will develop R-107 for treatment of COVID-19 associated lung disease.

Salzman Group is also developing R-107 for chlorine inhalation lung injury.

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600016C.

Salzman Group will make an application for an additional BARDA contract to develop R-107 for treatment of COVID-19 associated lung disease.

The potential total funding under the BARDA Contract for development of R-107 for CILI is USD 84.9m.

If Salzman Group's application for a new BARDA contract for development of R-107 for COVID-19 associated lung disease is successful, Salzman Group may...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT